10,997 Shares in CVS Health Corporation $CVS Bought by Vega Investment Solutions

Vega Investment Solutions purchased a new position in CVS Health Corporation (NYSE:CVS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,997 shares of the pharmacy operator’s stock, valued at approximately $1,138,000.

Several other institutional investors have also added to or reduced their stakes in CVS. BlackRock Inc. purchased a new stake in CVS Health during the 2nd quarter valued at about $12,747,462,000. State Street Corp increased its stake in CVS Health by 2.1% in the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after purchasing an additional 1,245,457 shares during the period. Capital International Investors increased its stake in CVS Health by 3.4% in the 4th quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock worth $2,189,793,000 after purchasing an additional 900,153 shares during the period. Norges Bank bought a new stake in CVS Health in the fourth quarter valued at approximately $1,666,265,000. Finally, Morgan Stanley boosted its stake in shares of CVS Health by 6.3% during the fourth quarter. Morgan Stanley now owns 20,373,774 shares of the pharmacy operator’s stock valued at $1,616,863,000 after purchasing an additional 1,211,631 shares during the period. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Stock Performance

NYSE:CVS opened at $94.06 on Tuesday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. The firm’s fifty day simple moving average is $101.88 and its 200 day simple moving average is $89.08. The stock has a market cap of $120.31 billion, a P/E ratio of 24.88, a price-to-earnings-growth ratio of 0.85 and a beta of 0.61. CVS Health Corporation has a twelve month low of $69.51 and a twelve month high of $110.68.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business had revenue of $106.10 billion during the quarter, compared to analyst estimates of $100.03 billion. During the same period in the prior year, the business earned $1.81 EPS. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, research analysts predict that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Thursday, July 23rd. CVS Health’s dividend payout ratio is presently 70.37%.

Analysts Set New Price Targets

Several research analysts recently commented on CVS shares. DA Davidson lifted their target price on shares of CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. HSBC reissued a “hold” rating and issued a $103.00 price target on shares of CVS Health in a report on Monday, July 6th. Truist Financial boosted their price objective on shares of CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Wells Fargo & Company increased their target price on shares of CVS Health from $103.00 to $123.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Finally, Cantor Fitzgerald raised their target price on CVS Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 7th. Twenty-two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and an average target price of $107.17.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.